Cuban drug against COVID-19 will be tested in the US, Brazil, and Mexico

The Cuban drug Itolizumab developed together with an Indian company, received authorization to begin a phase III clinical trial in patients with COVID-19 in the United States, Mexico, and Brazil. The news was announced on Twitter by the Center for Molecular Immunology (CIM) of Havana, the institution in charge of its development in collaboration with …

Continue reading